Precision Medicine and the “Slow Death” of Transplant in Lymphoma

The End of One-Size-Fits-All: The Precision Revolution in Lymphoma Treatment

For decades, the approach to treating lymphoma was largely a matter of broad categorization. If a patient had a specific type of lymphoma, they received the standard “gold-standard” regimen. However, the landscape is undergoing a seismic shift. We are moving away from broad-spectrum chemotherapy toward highly specific, molecularly defined interventions.

According to Craig H. Moskowitz, MD, a professor of medicine at the Miller School of Medicine of the University of Miami Health System, precision oncology—once viewed as an aspirational holy grail—is rapidly becoming the clinical standard. The goal is no longer just to treat the cancer, but to treat the specific molecular signature of that individual’s tumor.

Moving Beyond “Lumping”: The Importance of Molecular Profiling

One of the most significant hurdles in hematology has been the tendency to “lump” disease subtypes together. For instance, Diffuse Large B-cell Lymphoma (DLBCL) and Mantle Cell Lymphoma (MCL) are not single diseases, but rather collections of sub-diseases that behave incredibly differently.

The future of care lies in sequencing the tumor up front. In the case of MCL, the presence of abnormalities in p53—specifically a p53 mutation or abnormalities in chromosome 17p—is a critical marker. For these patients, aggressive therapy is often not beneficial. Instead, clinicians are moving toward gentler treatment that proves more effective for this specific molecular profile.

“The field will move forward by looking at subsets of patients and defining which subset needs to receive more modern therapeutics.” Craig H. Moskowitz, MD, Sylvester Comprehensive Cancer Center

The Current State of Curable Lymphomas

Even as the focus is shifting toward precision, the baseline for certain lymphomas remains strong. For example, untreated Hodgkin lymphoma—which affects about 9000 patients each year in the US—sees a cure rate that approaches 90%. Similarly, close to 80% of patients with DLBCL are cured with their first treatment.

The challenge now is the remaining 20% of DLBCL patients and those with relapsed/refractory Hodgkin lymphoma. For these individuals, the “laundry list” of traditional drugs is being replaced by targeted immunotherapies.

The New Arsenal: CAR T-Cells, T-Cell Engagers, and PROTACs

The pharmacological toolkit for lymphoma is expanding beyond traditional cytotoxic agents. We are seeing the rise of several novel classes of drugs:

• CAR T-cell Therapy: Engineered T-cells that specifically target cancer cells. In large B-cell lymphoma, these have been shown to be superior to traditional transplant methods.
• T-cell Engagers: These agents act as a bridge, bringing the body’s immune T-cells directly to the cancer cells to destroy them.
• PROTACs (Proteolysis Targeting Chimeras): These are “degraders” rather than inhibitors. Instead of just blocking a protein, they mark it for total destruction. BTK degraders are among the closest to clinical approval.

The “Gradual Death” of Stem Cell Transplantation

Perhaps the most surprising trend is the evolving role of autologous stem cell transplantation (ASCT). Once a cornerstone of relapsed lymphoma treatment, ASCT is now described as being in the midst of a slow death.

The reason is simple: efficacy and toxicity. With the advent of CAR T-cells and targeted agents, more patients are being cured upfront, and those who do relapse often have better options that don’t require the intensity of a transplant. In MCL and follicular lymphoma, the necessity of ASCT is diminishing rapidly as novel therapeutics provide safer, more effective alternatives.

For more information on the latest in immunotherapy, you can explore the National Cancer Institute’s guidelines on targeted therapy.

Frequently Asked Questions